61 results about "Channel modulator" patented technology

In certain embodiments, a vial adaptor comprises a housing configured to couple the adaptor with a vial, an access channel, a regulator channel, and a regulator assembly. The access channel is configured to facilitate withdrawal of fluid from the vial when the adaptor is coupled to the vial. The regulator channel is configured to facilitate a flow of a regulating fluid from the regulator assembly to compensate for changes in volume of a medical fluid in the vial. The regulator assembly can include a valve configured to transition between a closed configuration and an opened configuration.

The invention relates to a sodium channel regulator for inhibiting Nav1.8, and provides a compound as shown in a formula I which can be used as the sodium channel regulator for inhibiting Nav1.8, and an isomer of the compound, or a pharmaceutically acceptable salt of the compound, the invention also provides a pharmaceutical composition containing the compound and the isomer thereof, or the pharmaceutically acceptable salt thereof and a carrier or excipient, and a pharmaceutical application of the pharmaceutical composition as a NaV1.8 inhibitor (such as pain, respiratory diseases, neurological disorders, mental diseases and the like).

Aspects of the present disclosure relate generally to systems and methods for use in the implementation and / or operation of quantum information processing (QIP) systems, and more particularly, to a double individual-addressing multi-beam Raman system for use in QIP systems. A technique is described in which a first multi-channel modulator (MCM), a first telecentric zoom lens, and a first interleaver that form a first optical path of the Raman system that receives a first array of beams and adjusts the first array of beams to individually address atomic-based qubits in a chain from a first direction. Moreover, a second MCM, a second telecentric zoom lens, and a second interleaver form a second optical path of the Raman system that receives a second array of beams and adjusts the second arrays of beams to individually address the atomic-based qubits in the chain from a second direction different from the first direction.

Provided is a novel sodium channel modulator, in particular a Nav1.8 channel modulator, said compound being a compound of formula I, formula II, or formula III, an isomer thereof, a racemate thereof, or a pharmaceutically acceptable salt or prodrug thereof, wherein formula I is as shown.

The invention provides a compound as shown in a formula I which can be used as a sodium channel regulator, and a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition containing the compound and the stereoisomer, the tautomer or the pharmaceutically acceptable salt thereof and a carrier or excipient, and a pharmaceutical application of the pharmaceutical composition as a NaV1.8 inhibitor (such as pain, respiratory diseases, neurological disorders, mental diseases and the like).

Provided is a novel sodium channel modulator, in particular a Nav1.8 channel modulator, the compound having a formula I, a formula II, or a formula III, an isomer, a racemate, or a pharmaceutically acceptable salt or prodrug thereof, where the formula I is as shown in the specification. # imgabs0 #

Novel sodium channel modulator, in particular Nav1.8 channel modulator, sodium channel modulator having structure represented by formula I: # imgabs0 #

Provided in the present invention are a compound as represented by formula I which can be used as a sodium channel modulator, and a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition containing the compound and the stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a carrier or an excipient, and the pharmaceutical use thereof as an NaV1.8 inhibitor (against, for example, pain, respiratory diseases, neurological disorders, and mental diseases).

Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, wherein the compounds comprise a diazaspiroheptane core and left- and right-hand substitutions of the diazaspiroheptane core. Also disclosed herein are methods using the compounds to treat a disease or condition relating to aberrant function or activity of a T-type calcium channel.

Provided in the present invention are a compound as represented by formula I which can be used as a sodium channel modulator, and a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition containing the compound and the stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a carrier or an excipient, and the pharmaceutical use thereof as an NaV1.8 inhibitor (against, for example, pain, respiratory diseases, neurological disorders, and mental diseases).

Provided are macrocyclic sodium channel modulators, particularly Nav1.8 channel modulators, which are compounds of Formula I, preferably Formula I1, I2, or I3, isomers, racemate, or pharmaceutically acceptable salts thereof, where the definitions of the groups and substituents are as described in the specification.

The present invention provides, inter alia, apelin receptor agonists having increased half-life, reduced desensitization, improved apelin receptor signaling properties (e.g., bias of G a signaling over arrestin signaling), enhanced stability, and / or enhanced binding to apelin receptors.

Fused heteroaryl compounds and compositions useful for preventing and / or treating a disease or condition related to aberrant function of voltage-gated sodium ion channels, e.g., an abnormal, delayed / persistent sodium current. Treatment methods for a disease or condition related to aberrant function of sodium ion channels are also provided herein, including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders.

The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.

Aspects of the present disclosure relate generally to systems and methods for use in the implementation and / or operation of quantum information processing (QIP) systems, and more particularly, to a double individual-addressing multi-beam Raman system for use in QIP systems. A technique is described in which a first muti-channel modulator (MCM), a first telecentric zoom lens, and a first interleaver that form a first optical path of the Raman system that receives a first array of beams and adjusts the first array of beams to individually address atomic-based qubits in a chain from a first direction. Moreover, a second MCM, a second telecentric zoom lens, and a second interleaver form a second optical path of the Raman system that receives a second array of beams and adjusts the second arrays of beams to individually address the atomic-based qubits in the chain from a second direction different from the first direction.

Described herein, in part, are methods useful for treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as essential tremor, in a subject in need thereof, comprising administering a T-type calcium channel inhibitor in combination with at least one of propranolol, primidone, topiramate, or a pharmaceutically acceptable salt thereof. Also disclosed herein are compositions comprising the T-type calcium channel inhibitor and at least one of propranolol, primidone, topiramate, or a pharmaceutically acceptable salt thereof.

The invention provides a novel sodium channel regulator compound and application thereof, and the sodium channel regulator has a brand new structure and has an excellent in-vitro inhibition effect on Nav 1.8. The compound or the pharmaceutically acceptable salt thereof can be used for treating sodium channel related diseases, including pain, multiple sclerosis, fibula amyotrophy, incontinence, pathological cough, arrhythmia and the like.

The present disclosure provides Pattern D, i.e., a crystalline form of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide hydrochloride salt trihydrate (Compound 1). The present disclosure also provides pharmaceutical compositions comprising Compound 1 in the form of Pattern D, as well as methods of treating neurological and psychiatric disorders by administering to a subject in need thereof Compound 1 in the form of Pattern D or a pharmaceutical composition comprising Compound 1 in the form of Pattern D.

Provided are a novel sodium channel modulator compound and a use thereof. The sodium channel modulator has a completely new structure as shown in formula I, and exhibits excellent in vitro inhibitory effects against Nav 1.8. The compound or a pharmaceutically acceptable salt thereof can be used for treating sodium channel-related diseases, including diseases such as pain, multiple sclerosis, Charcot-Marie-Tooth disease, incontinence, pathological cough, or arrhythmia.

Provided, in part, are compounds of Formula I:pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with the activity of sodium channels. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

The invention discloses a method for processing data loss caused by frequency offset in request-system satellite data transmission, and belongs to the technical field of satellite communication. The two-channel modulator of the dual-channel request system satellite respectively sends request frames to the data processor, and the request frames are combined and then output to the solid-state memory; the solid-state memory sends playback data of a corresponding data frame number of a single path to the data processor according to the frame number of the received request frames; the data processor averagely divides the received single-path playback data into two paths, respectively performs data processing, and generates a full identification signal; after data processing is completed, the data are output to a two-channel modulator according to the number of request frames of the path; when the full identification signal of any one of the two channels is 1, request frame combination is stopped, and at the moment, the solid-state memory pauses data playback. By detecting the capacity of the cached data in the caches in the two coding processing units in real time, the problem of data loss caused by frequency offset of a modulator clock crystal oscillator in satellite request system data transmission is reliably solved in real time.

The disclosure provides a composition configured for oral use, the composition including at least one active ingredient, an ion channel modulator which binds to one or more receptors selected from TRPA1, TRPV1, TRPV3, TRPM8, NaV1.7, and combinations thereof; and at least one filler.

Described herein, in part, are dosage forms and compositions useful for preventing and / or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.

Disclosed herein are compounds of formulae (I), (II), and (III) and a pharmaceutically acceptable salts thereof. Also disclosed herein are uses of compounds of formulae (I), (II), and (III), as well as pharmaceutically acceptable salts thereof in the potential treatment or prevention of a disease or disorder which is modulated by the Kv3 potassium channels in a subject in need thereof. Also disclosed are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of a disease or disorder which is modulated by the Kv3 potassium channels.

Disclosed are therapeutic methods for treating a disease or condition characterized by decreased expression or reduced function of an ion channel using an amphotericin B derivative, or an amphotericin B derivative and an ion channel modulator. The methods can be used to treat cystic fibrosis.

Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, wherein the compounds comprise an azaspirononane core and left- and right-hand substitutions of the azaspirononane core. Also disclosed herein are methods using the compounds to treat a disease or condition relating to aberrant function or activity of a T-type calcium channel.

Provided is a novel sodium channel modulator, and particularly an Nav1.8 channel modulator. The sodium channel modulator has a structure as shown in the following formula I.